Liminatus Pharma, Inc. Class A Common Stock
LIMNNASDAQHealthcare● Active
$0.14
+$0.00(+1.42%)
Market Cap$3837177
P/E Ratio—
52W High$33.66
52W Low$0.132
Liminatus Pharma, Inc. Class A Common Stock (LIMN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LIMN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.43 | $-0.40 | $-0.15 | $-0.08 | $0.13 |
| Wtd Avg Shares | 0.02B | 0.01B | 0.01B | 0.03B | 0.03B |
| EBITDA | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Liminatus Pharma, Inc. Class A Common Stock data
About Liminatus Pharma, Inc. Class A Common Stock (LIMN) Income Statement
Liminatus Pharma, Inc. Class A Common Stock (LIMN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LIMN reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
LIMN · 4 questionsLiminatus Pharma, Inc. Class A Common Stock (LIMN) reported revenue of $0.00B for 2025, down —% year-over-year.
LIMN revenueLIMN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09